3 research outputs found
A Neurodegenerative Vascular Burden Index and the Impact on Cognition
A wide range of vascular burden factors have been identified to impact vascular function and structure as indicated by carotid intima-media thickness (IMT). On the basis of their impact on IMT, vascular factors may be selected and clustered in a vascular burden index (VBI). Since many vascular factors increase the risk of Alzheimer's disease (AD), a multifactorial neurodegenerative VBI may be related to early pathological processes in AD and cognitive decline in its preclinical stages.We investigated an elderly cohort at risk for neurodegeneration (TREND study, n = 1102) for the multifactorial influence of vascular burden factors on IMT measured by ultrasound. To create a VBI for this cohort, vascular factors and their definitions (considering medical history, medication and/or blood marker data) were selected based on their statistical effects on IMT in multiple regressions including age and sex. The impact of the VBI on cognitive performance was assessed using the Trail-Making Test (TMT) and the CERAD neuropsychological battery.IMT was significantly predicted by age (standardized β = .26), sex (.09; males > females) and the factors included in the VBI: obesity (.18), hypertension (.14), smoking (.08), diabetes (.07), and atherosclerosis (.05), whereas other cardiovascular diseases or hypercholesterolemia were not significant. Individuals with 2 or more VBI factors compared to individuals without had an odds ratio of 3.17 regarding overly increased IMT (≥1.0 mm). The VBI showed an impact on executive control (log(TMT B-A), p = .047) and a trend towards decreased global cognitive function (CERAD total score, p = .057) independent of age, sex and education.A VBI established on the basis of IMT may help to identify individuals with overly increased vascular burden linked to decreased cognitive function indicating neurodegenerative processes. The longitudinal study of this risk cohort will reveal the value of the VBI as prodromal marker for cognitive decline and AD
Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies
Parkinson’s disease (PD) is an example for a complex field of research, which is driven by themultifactorial etiology, the heterogeneity in phenotype and the variability in disease progression,as well as the presence of a long pre-diagnostic period, called prodromal PD, lasting up to decades(Postuma et al., 2010). The very slow, so far inevitably progressive, neurodegenerative process andthe multidimensional heterogeneity of symptoms in kind (motor and non-motor), time of onsetand speed of progression call for prediction markers and progression markers to understand theonset of neurodegeneration and its course. These markers would also help to establish endpointsfor neuroprotective treatment strategies aiming to modify disease progression. Because of thecomplexity, heterogeneity, and the progressive nature of PD, such predictive and progressionmarkers can only be identified in large cohorts and in studies with a longitudinal design
The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases
AbstractBiobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's Disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme - Neurodegenerative Disease Research (JPND), that aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer’s disease (AD) and Parkinson’s disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized preanalytical procedures (SOP) and stored at Integrated BioBank of Luxembourg (IBBL). The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia (VaD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), PD, PD with dementia, and dementia with Lewy bodies (DLB). The virtual biobank contains information on over 8600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank